KEGG   DISEASE: 膵癌
エントリ  
H00019                                                             
名称    
膵癌
  上位グループ
固形腫瘍 [DS:H02421]
概要    
Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors. The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.
カテゴリ  
がん
階層分類  
ICD-11 による疾患分類 [BR:jp08403]
 02 腫瘍
  悪性腫瘍, ただしリンパ, 造血, 中枢神経系または関連組織の原発腫瘍を除く
   悪性腫瘍, 原発性と確定または推定されるもの, 明示された部位のもの, ただしリンパ, 造血, 中枢神経系, 関連組織を除く
    消化器の悪性腫瘍
     2C10  膵臓の悪性腫瘍
      H00019  膵癌
パスウェイに基づく疾患分類 [BR:jp08402]
 複製と修復
  nt06506  二本鎖切断修復
   H00019  膵癌
  nt06508  鎖間架橋修復
   H00019  膵癌
 シグナル伝達
  nt06526  MAPK シグナリング
   H00019  膵癌
  nt06543  NRG-ERBB シグナリング
   H00019  膵癌
疾患パスウェイ
hsa05212  膵癌
ネットワーク
nt06262 Pancreatic cancer
nt06506 Double-strand break repair
nt06508 Interstrand crosslink repair
nt06543 NRG-ERBB signaling
病因遺伝子 
KRAS [HSA:3845] [KO:K07827]
TP53 [HSA:7157] [KO:K04451]
SMAD4 [HSA:4089] [KO:K04501]
STK11 [HSA:6794] [KO:K07298]
ACVR1B [HSA:91] [KO:K13567]
ERBB2 (overexpression) [HSA:2064] [KO:K05083]
CDKN2A (mutation, deletion, promoter methylation) [HSA:1029] [KO:K06621]
NRG1 (fusion) [HSA:3084] [KO:K05455]
(PNCA1) PALLD [HSA:23022] [KO:K22029]
(PNCA2) BRCA2 [HSA:675] [KO:K08775]
(PNCA3) PALB2 [HSA:79728] [KO:K10897]
(PNCA4) BRCA1 [HSA:672] [KO:K10605]
(PNCA5) RABL3 [HSA:285282] [KO:K07933]
治療薬   
マイトマイシンC [DR:D00208]
レボホリナートカルシウム水和物 [DR:D11555]
シクロホスファミド水和物 [DR:D00287]
フルオロウラシル [DR:D00584]
シタラビン [DR:D00168]
ゲムシタビン塩酸塩 [DR:D01155]
テガフール・ウラシル [DR:D02131]
テガフール・ギメラシル・オテラシルカリウム [DR:D06399]
ドキソルビシン塩酸塩 [DR:D01275]
パクリタキセル [DR:D00491]
イリノテカン塩酸塩水和物 [DR:D01061]
エルロチニブ塩酸塩 [DR:D04023]
オキサリプラチン [DR:D01790]
オラパリブ [DR:D09730] (BRCA遺伝子変異陽性)
リンク   
ICD-11: 2C10.0
MeSH: D010190
OMIM: 260350 606856 613347 613348 614320 618680
文献    
PMID:12459728 (KRAS, TP53, SMAD4, STK11, ERBB2, CDKN2A, BRCA2)
  著者
Bardeesy N, DePinho RA.
  タイトル
Pancreatic cancer biology and genetics.
  雑誌
Nat Rev Cancer 2:897-909 (2002)
DOI:10.1038/nrc949
文献    
  著者
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.
  タイトル
Genetics and biology of pancreatic ductal adenocarcinoma.
  雑誌
Genes Dev 20:1218-49 (2006)
DOI:10.1101/gad.1415606
文献    
  著者
Bardeesy N, Sharpless NE, DePinho RA, Merlino G.
  タイトル
The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.
  雑誌
Semin Cancer Biol 11:201-18 (2001)
DOI:10.1006/scbi.2000.0371
文献    
  著者
Hruban RH, Goggins M, Parsons J, Kern SE.
  タイトル
Progression model for pancreatic cancer.
  雑誌
Clin Cancer Res 6:2969-72 (2000)
文献    
PMID:11248065 (ACVR1B)
  著者
Su GH, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, Kern SE
  タイトル
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
  雑誌
Proc Natl Acad Sci U S A 98:3254-7 (2001)
DOI:10.1073/pnas.051484398
文献    
PMID:31164372 (NRG1)
  著者
Aguirre AJ
  タイトル
Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer.
  雑誌
Clin Cancer Res 25:4589-4591 (2019)
DOI:10.1158/1078-0432.CCR-19-1280
文献    
PMID:17194196 (PALLD)
  著者
Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA, George RD, Whitcomb DC, Brentnall TA
  タイトル
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism.
  雑誌
PLoS Med 3:e516 (2006)
DOI:10.1371/journal.pmed.0030516
文献    
PMID:19264984 (PALB2)
  著者
Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP
  タイトル
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
  雑誌
Science 324:217 (2009)
DOI:10.1126/science.1171202
文献    
PMID:18762988 (BRCA1)
  著者
Al-Sukhni W, Rothenmund H, Borgida AE, Zogopoulos G, O'Shea AM, Pollett A, Gallinger S
  タイトル
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
  雑誌
Hum Genet 124:271-8 (2008)
DOI:10.1007/s00439-008-0554-0
文献    
PMID:31406347 (RABL3)
  著者
Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wucherpfennig JI, Kim AJ, Henderson JE, Gonyo P, Brandt A, Lorimer E, Unger B, Prokop JW, Heidel JR, Wang XX, Ukaegbu CI, Jennings BC, Paulo JA, Gableske S, Fierke CA, Getz G, Sunyaev SR, Wade Harper J, Cichowski K, Kimmelman AC, Houvras Y, Syngal S, Williams C, Goessling W
  タイトル
Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer.
  雑誌
Nat Genet 51:1308-1314 (2019)
DOI:10.1038/s41588-019-0475-y
LinkDB    

» English version

DBGET integrated database retrieval system